Lastly, since the new frontier of cancer immunotherapy is the employment of immune checkpoint inhibitors (i.e., against PD-1, PD-L1, CTLA-4) further studies are needed to clarify whether IL-33 conditioning may increase the therapeutic response to checkpoint blockade in cancer patients. The gene discussed is IL33; the disease is cancer.